Musso muscle boosts ReViral
ReViral, a clinical-stage company developing novel antiviral compounds that target respiratory syncytial virus, has appointed ace operator Alan Musso as chief financial officer.
With more than 30 years of financial and operational leadership experience in both publicly-traded and private biopharma companies, Musso will succeed Max Herrmann who will remain in a consulting capacity to help steer a seamless transition.
Reviral is based at the burgeoning Stevenage Bioscience Catalyst. CEO Alex Sapir said: ““Alan is an exceptional addition to the team. His distinguished track record of building finance and accounting organisations at several leading biopharma companies, along with his experience raising capital in both private and public settings will be invaluable as the company enters its next stage of development with our lead product, sisunatovir.”
Musso joins from Peloton Therapeutics, Inc., a company focused on the discovery and development of novel small molecule therapeutics for the treatment of cancer.
During his tenure as CFO and treasurer at Peloton, the company completed a $150 million mezzanine financing and was poised for an initial public offering when the company accepted an acquisition offer from Merck & Co.